{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:31:50Z","timestamp":1784694710095,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007847","name":"Jilin Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS117"],"award-info":[{"award-number":["YDZJ202201ZYTS117"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.tranon.2025.102385","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:54:03Z","timestamp":1744365243000},"page":"102385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Establishment of patient-derived xenograft models in Chinese patients with multiple myeloma: Insights into therapeutic responsiveness and molecular subtyping"],"prefix":"10.1016","volume":"56","author":[{"given":"Xueju","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangzhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lintao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.tranon.2025.102385_bib0001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.tranon.2025.102385_bib0002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMa"},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0004","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0005","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC. Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2025.102385_bib0006","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: a systematic analysis for the Global burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMa Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2025.102385_bib0007","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2025.102385_bib0008","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2018-99-111924","article-title":"VTD (Bortezomib\/Thalidomide\/Dexamethasone) As pretransplant induction therapy for Multiple myeloma: definitive results of a randomized phase 3 Pethema\/GEM study","volume":"132","author":"Rosinol Dachs","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102385_bib0009","first-page":"11","article-title":"Understanding the bioactivity and prognostic implication of commonly used surface antigens in multiple myeloma[J]","author":"Lebel","year":"2022","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.tranon.2025.102385_bib0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PAI.0b013e3181cf1126","article-title":"MUM1\/IRF4: a review. [J]","volume":"18","author":"Gualco","year":"2010","journal-title":"Applied Immunohistochemistry & Molecular Morphology"},{"issue":"4","key":"10.1016\/j.tranon.2025.102385_bib0011","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4274\/tjh.galenos.2022.2022.0046","article-title":"Predictive immune markers for disease progression in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"39","author":"\u0130\u015fg\u00f6r","year":"2022","journal-title":"Turk. J. Haematol."},{"issue":"11","key":"10.1016\/j.tranon.2025.102385_bib0012","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study","volume":"8","author":"Kelly","year":"2021","journal-title":"Lancet Haematol."},{"issue":"22","key":"10.1016\/j.tranon.2025.102385_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225335","article-title":"CD46-ADC reduces the engraftment of multiple Myeloma patient-derived xenografts","volume":"15","author":"VanWyngarden","year":"2023","journal-title":"Cancers. (Basel)"},{"issue":"3","key":"10.1016\/j.tranon.2025.102385_bib0014","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin. Oncol. Nurs."},{"issue":"24","key":"10.1016\/j.tranon.2025.102385_bib0015","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1158\/1078-0432.CCR-23-0229","article-title":"Comprehensive single-cell immune profiling defines the patient multiple myeloma microenvironment following oncolytic virus therapy in a phase Ib trial","volume":"29","author":"Nawrocki","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.tranon.2025.102385_bib0016","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0017","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1186\/s12885-023-11434-9","article-title":"Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges","volume":"23","author":"Gao","year":"2023","journal-title":"BMC. Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2025.102385_bib0018","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","article-title":"Towards precision oncology with patient-derived xenografts","volume":"19","author":"Zanella","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0019","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102385_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7030041","article-title":"Using PDX for preclinical cancer drug discovery: the evolving field","volume":"7","author":"Williams","year":"2018","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.tranon.2025.102385_bib0021","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.tranon.2025.102385_bib0022","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V99.11.4100","article-title":"The nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse","volume":"99","author":"Lock","year":"2002","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.tranon.2025.102385_bib0023","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-16-2703","article-title":"B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2025.102385_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119546","article-title":"NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease","volume":"10","author":"Lawson","year":"2015","journal-title":"PLoS. One"},{"issue":"11","key":"10.1016\/j.tranon.2025.102385_bib0025","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.tranon.2025.102385_bib0026","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1200\/JCO.2011.36.9678","article-title":"Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft","volume":"30","author":"Morelli","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2025.102385_bib0027","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","article-title":"A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer","volume":"10","author":"Hidalgo","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.tranon.2025.102385_bib0028","first-page":"3779","article-title":"Establishment of the PDTX model of gynecological tumors","volume":"11","author":"Yang","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.tranon.2025.102385_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41467-020-20208-x","article-title":"The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation","volume":"12","author":"Fan","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.tranon.2025.102385_bib0030","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3975","article-title":"Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by patient-derived xenograft models[J]","volume":"27","author":"Yang","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/j.tranon.2025.102385_bib0031","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.tranon.2025.102385_bib0033","unstructured":"Bushnell B. BBMap. 2015, https:\/\/sourceforge.net\/projects\/bbmap\/."},{"key":"10.1016\/j.tranon.2025.102385_bib0034","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"Li","year":"2013","journal-title":"arXiv preprint"},{"key":"10.1016\/j.tranon.2025.102385_bib0035","unstructured":"http:\/\/broadinstitute.github.io\/picard\/."},{"issue":"5","key":"10.1016\/j.tranon.2025.102385_bib0036","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0037","doi-asserted-by":"crossref","first-page":"49.","DOI":"10.1186\/s13059-015-0617-1","article-title":"CopywriteR: DNA copy number detection from off-target sequence data","volume":"16","author":"Kuilman","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.tranon.2025.102385_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC. Bioinformatics."},{"issue":"3","key":"10.1016\/j.tranon.2025.102385_bib0039","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1101\/gr.257246.119","article-title":"Accurate and efficient detection of gene fusions from RNA sequencing data","volume":"31","author":"Uhrig","year":"2021","journal-title":"Genome Res."},{"issue":"2","key":"10.1016\/j.tranon.2025.102385_bib0040","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr. Oncol."},{"issue":"45","key":"10.1016\/j.tranon.2025.102385_bib0041","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1038\/s41388-022-02494-5","article-title":"Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma","volume":"41","author":"Guo","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2025.102385_bib0042","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-2703","article-title":"B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy[J]","author":"Zhang","year":"2017","journal-title":"Clinical Cancer Research An Official Journal of the American Association for Cancer Research"},{"issue":"47","key":"10.1016\/j.tranon.2025.102385_bib0043","doi-asserted-by":"crossref","first-page":"eabg9551","DOI":"10.1126\/sciadv.abg9551","article-title":"Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications","volume":"7","author":"Bhalla","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0044","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"Mohan","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.tranon.2025.102385_bib0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.tranon.2025.102385_bib0046","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cancergen.2014.06.025","article-title":"From chromosomal abnormalities to the identification of target genes in mouse models of breast cancer","volume":"207","author":"Fabris","year":"2014","journal-title":"Cancer Genet."},{"issue":"1","key":"10.1016\/j.tranon.2025.102385_bib0047","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12920-021-00883-5","article-title":"Gene networks and transcriptional regulators associated with liver cancer development and progression","volume":"14","author":"Meier","year":"2021","journal-title":"BMC. Med. Genomics."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325001160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325001160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T02:32:34Z","timestamp":1746844354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"alternative-id":["S1936523325001160"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102385","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment of patient-derived xenograft models in Chinese patients with multiple myeloma: Insights into therapeutic responsiveness and molecular subtyping","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102385"}}